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Abstract  15 
Salmonella causes grave systemic infections in humans and other animals and provides a paradigm for 16 
other diseases where the bacteria have both intracellular and extracellular lifestyles.  17 
New generations of vaccines rely on the essential contribution of the antibody responses for their 18 
protection. The quality, antigen specificity and functions associated with antibody responses to this 19 
pathogen have been elusive for a long time. Recent approaches that combine studies in humans and 20 
genetically manipulated experimental models, and exploit awareness of the location and within-host life 21 
cycle of the pathogen, are shedding light on how humoral immunity to Salmonella operates. However, 22 
this area of research remains full of controversy and discrepancies. 23 
The overall scenario indicates that antibodies are essential for resistance against systemic Salmonella 24 
infections and can express the highest protective function when operating in conjunction with cell-25 
mediated immunity. Antigen specificity, isotype profile, Fc-gamma receptor usage and complement 26 
activation are all intertwined factors that still arcanely influence antibody-mediated protection to 27 




Several serovars of Salmonella enterica cause systemic diseases in humans and other animals. The global 30 
estimated burden of typhoid fever (serovar Typhi) is over 21M illnesses and 200,000 deaths with sustained 31 
high incidence in Southeast Asia and endemic/epidemic occurrence increasingly reported in Africa (1-6). 32 
Paratyphoid fever (serovars Paratyphi A, B and C) has an estimated 5.4M illnesses worldwide (3). Invasive 33 
non-typhoidal Salmonella (iNTS) serovars (e.g. Typhimuriun and Enteritidis) are a leading cause of lethal 34 
sepsis and severe relapsing infections in young children and immune-compromised individuals, especially 35 
in countries of the sub-Saharan African region (6-12) with an estimated 3.8M illnesses leading to 680,000 36 
deaths annually and very high case-fatality ratios (20%) (7, 11). Antimicrobial resistance (AMR) is an 37 
increasing problem in tackling many bacteria including Salmonella (7, 11, 13-15).  38 
 39 
Why is it important to gain a better understanding of antibody-mediated immunity to Salmonella? 40 
There is extensive international consensus on the urgent need for better and affordable vaccines against 41 
systemic Salmonella infections. Vaccination has the potential for a high economic and health impact in 42 
fighting AMR infections (16-19). Several classes of vaccines against systemic Salmonella disease have been 43 
considered in the past decades (20, 21). These vary in their ability to induce protective cell-mediated and 44 
humoral immunity with, broadly speaking, live attenuated vaccines being more efficient than non-living 45 
preparations at eliciting Th1 type T-cell immunity known to contribute to host resistance to this bacterium 46 
(22, 23).  47 
Despite the superior protective activity shown in animal models, live Salmonella vaccines can cause lethal 48 
infections in immune-compromised hosts (24-27). Mutants of Salmonella, including those that have been 49 
considered so far as vaccine candidates, retain virulence and can rapidly kill immune-suppressed mice 50 
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(24-27). Mice that lack T-cell functions (25, 27) and mice co-infected with malaria are very susceptible to 51 
infection with live Salmonella including mutants that have been considered as vaccine candidates (28, 52 
29). Efforts to identify single gene mutations for the development of live vaccine candidates that would 53 
be completely safe (totally unable to grow to high numbers) in severely immune-deficient animals have 54 
been unsuccessful (24). This raises some concerns for the use of live vaccines in endemic areas with a 55 
higher incidence of immune-suppressive conditions. For example, HIV and malaria are co-morbidities that 56 
make humans more susceptible to systemic Salmonella infection leading to severe, often fatal disease, 57 
and therefore pose dangers to the use of live vaccines (30, 31). These co-morbidities are widespread and 58 
epidemiologically co-localize with areas of the developing world where there is a high incidence of 59 
epidemic or endemic systemic salmonelloses and therefore where anti-Salmonella vaccines are most 60 
needed (9, 20, 31, 32).  61 
Mainly for safety reasons, non-living vaccines are currently being considered as prime candidates for 62 
immunization against Salmonella diseases. The protective ability of these vaccines relies largely on the 63 
induction of antibodies. If we are to use non-living vaccines as tools against systemic salmonelloses, it is 64 
therefore essential to rationally optimize the antibody responses induced by these preparations. This 65 
knowledge would also be immensely useful to understand how those comorbidities that impair antibody-66 
mediated functions increase susceptibility to disease and to design vaccine strategies that can at least in 67 
part reverse these immune suppressing conditions. This will need to be based on a clearer understanding 68 
of the qualitative and functional features of the protective antibody response against Salmonella.  69 
This article will briefly outline the factors that influence the protective efficacy of the antibody response 70 
to systemic Salmonella infections and will embed antibody functions in the context of the location and 71 
spread of the bacteria during the infection process. The mini-review will also highlight the interactions 72 
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and dual requirement of T and B-cell mediated immunity both in the engenderment of antibody and T-73 
cell responses and in the expression of in vivo resistance to the pathogen. 74 
 75 
How can antibodies protect against a pathogen that has an intracellular lifestyle? 76 
The relative importance of antibodies and cellular immunity in host resistance to systemic Salmonella 77 
infections has been a matter of debate for a long time.  78 
The controversy initially originated from uncertainties in the location of the bacteria within the tissues of 79 
an infected host. It is undisputable that in many animal species, including humans, Salmonella resides 80 
inside phagocytes and grows within these cells using an armoury of genes and effectors to foster its 81 
replication and evade intracellular killing (24, 33-40). Evidence from the mouse model on the role of the 82 
phagocyte innate resistance gene Ity (now known as Scla11a1) in the control of bacterial division in vitro 83 
and in vivo as well as  studies where the bacteria could be seen to grow within cultured phagocytic cells 84 
corroborated these views (41-44). However, evidence for extracellular growth and lack of intracellular 85 
replication had also been produced, albeit based on electron microscopy studies where infections were 86 
allowed to progress to very high, pre-mortem, bacterial numbers in the tissues. In these studies 87 
intracellular bacteria were seen to undergo various stages of degradation inside macrophages and 88 
granulocytes and therefore it was inferred that Salmonella was more likely to be an extracellular pathogen 89 
and its virulence directly related to its antiphagocytic property (45).  90 
The debate was further fuelled by immunological studies in both experimental animals and humans. On 91 
the one hand evidence was provided for the protective role of antibodies being limited to the very early 92 
stages of parenteral experimental infections, when the bacteria have not yet reached an intracellular 93 
location, with no detectable effect on their later growth in the tissues (46, 47); on the other hand the 94 
6 
 
protective effect of whole-cell non-living typhoid vaccines, that induce mainly humoral immunity, and Vi 95 
vaccines that do not directly contain Salmonella-specific T-cell antigens was undeniable (48-53). However, 96 
protection by passive transfer of antibodies or T-cells alone and by non-living vaccines was seen only in 97 
host-pathogen interactions where the infection is naturally mild and sublethal, such as challenging 98 
resistant mice with either virulent or weakly virulent strains or susceptible mice with weakly virulent 99 
strains (46, 50). 100 
These discrepant views on the relative importance of humoral and cellular immunity to Salmonella were 101 
largely reconciled by studies showing that passive transfer of both antibodies and T-cells, but neither 102 
alone, could protect recipient innately susceptible animals against fatal systemic Salmonella disease (54).  103 
More recently the essential role of both antibodies and T-cells in host resistance to Salmonella has been 104 
corroborated by additional evidence obtained from human studies. For example, clinical observations 105 
indicate that lack of antibodies at young age correlates with the incidence of iNTS in African children (55, 106 
56), despite these children acquire Salmonella-specific CD4 Th1 cell immunity very early in life; only when 107 
antibodies are developed in addition to T-cell immunity full protection is achieved (57). This resistance is 108 
then abrogated by comorbidities that can affect either cellular or antibody-mediated functions (29, 58-109 
62). For example, HIV that has a profound effect of CD4+ T-cell immunity and malaria that impairs 110 
phagocyte functions increase susceptibility to systemic Salmonella infections such as iNTS. A similar 111 
increase in susceptibility is seen in patients with deficiencies in cytokines such as IFNγ and IL12 and in 112 





Salmonella: a bacterium with a complex intra and extracellular pathogenesis. Where do antibodies 116 
target Salmonella? 117 
Salmonella infections are normally acquired by the oral route and reach the blood  after invading the 118 
gastrointestinal tract (68). In the blood, the bacteria can be found either as extracellular bacteria or 119 
associated with CD18+ cells (69) (Figure 1, A). Extracellular Salmonella in the blood can be targeted by 120 
antibodies that enhance their uptake and killing by resident phagocytes of the spleen and liver (46, 70, 121 
71) and can potentially lyse them via activation of the complement classical pathway (56). From the blood, 122 
Salmonella reach an intracellular location within phagocytes of the liver, spleen and bone marrow (70, 72, 123 
73) (Figure 1, B). Early in infection Salmonella reaches mainly splenic red pulp (F4/80+, MSR-Alow) and 124 
marginal zone macrophages (MSR-A+) (74). In the liver, Salmonella localizes preferentially in the resident 125 
Kupffer cells. During the infection bacteria can also be found in dendritic cells or B-cells (36, 74-77). As the 126 
infection progresses and bacteria reside and possibly grow intracellularly (Figure 1, C), inflammatory cells 127 
infiltrate the initial unicellular foci of infection, to form multicellular pathological lesions surrounded by 128 
normal tissue (Figure 1, D). These lesions contain polymorphonuclear phagocytes (PMNs) during the first 129 
few days of infection, later replaced by inflammatory macrophages (36, 78).   130 
Once Salmonella have homed inside host cells, their intracellular location would render the bacteria 131 
inaccessible to antibodies, making it difficult to envisage a role of humoral immunity in protection. 132 
Detailed analysis of intracellular bacterial densities over the course of experimental infections in mice 133 
have shed light on how and where the bacteria can become vulnerable to antibodies. In fact, microscopic 134 
observation of immune-labelled and/or fluorochome-expressing intracellular bacteria in the spleen and 135 
liver revealed that the majority of infected phagocytes contain very low intracellular numbers at any time 136 
of the infection, irrespective of overall the net growth of the bacteria in the organs (77). The infection 137 
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process is underpinned both by intracellular growth/survival and by an increase in the number of infected 138 
cells and multicellular pathological lesions and not by increases in the number of visible intracellular 139 
bacterial per phagocytes (24, 77, 79) (Figure 1, D). This is due to the continuous re-distribution of the 140 
bacteria from infected host cells to uninfected ones, and in the spread of individual microorganisms to 141 
new infection foci (Figure 1, E), mediated by the Salmonella Type three secretion system (T3SS) encoded 142 
by the Salmonella Pathogenicity Island 2 (SPI-2) (80, 81). Salmonella infections are therefore dispersive 143 
processes where bacteria have an intracellular phase of growth and an extracellular one of spread. 144 
 145 
Is the dispersiveness of the infection a plausible explanation for the role of antibodies in protection 146 
against Salmonella? It would be reasonable to postulate that in a dispersive infection process, cell-147 
mediated immunity enhances the antimicrobial functions of phagocytes, therefore affecting the fate of 148 
the intracellular bacteria (82-86); antibodies would opsonise the extracellular bacteria in transit between 149 
cells and target them to activating cellular receptors, thus increasing the antimicrobial activity of 150 
otherwise naive phagocytes at new infection foci (87, 88). Antibodies would therefore be expected to 151 
have a major impact on the process.  152 
However, we know from a large body of data that antibodies alone, in the absence of cell-mediated 153 
immunity, are unable to modify the net growth rate of Salmonella in the spleen and liver of an infected 154 
experimental animal (21, 46, 50). For example, adoptive transfer of Salmonella specific immunoglobulins 155 
or immunisation with non-living vaccines surprisingly does not affect the growth curve of the bacteria in 156 
vivo.  An effect of antibodies is visible only in the first few hours of the infection where the initial kill of 157 
the inoculum is enhanced (46). This early protective effect of antibodies is more evident when 158 
experimental animals are challenged via the intraperitoneal route, where antibodies most likely 159 
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accelerate capture of the bacteria by peritoneal phagocytes and therefore abort extracellular growth in 160 
the peritoneal cavity. The use of molecularly tagged and therefore individually traceable, Salmonella 161 
populations, combined with mathematical modelling and statistical analysis of data has further confirmed 162 
the inability of antibody to significantly affect the growth and spread of bacteria in the body. This research 163 
approach has confirmed that, in the early stages of the infection, bacteria spread from cell to cell within 164 
each organ, later followed by systemic spread of bacterial populations between distant body sites 165 
coinciding with the appearance of bacteria in the blood (89). Using this system, it became clear that only 166 
live vaccines (which induce both humoral and cell-mediate immunity) would be able to control 167 
bacteraemia and restrain growth and spread of the bacteria in the body. Conversely, mice where 168 
antibodies were the only vaccine-mediated effector mechanisms (i.e. mice immunised with killed vaccines 169 
or depleted of T-cells after immunisation) would not be able to control the spread of the bacteria or abort 170 
bacteraemia (71).  171 
 172 
Antigen specificity and protection. Salmonella infections induce antibody responses against a large array 173 
of surface, periplasmic and cytoplasmic antigens in humans and other infected animals. Immuno-reactive 174 
antigens have been detected using ELISA, immunoblotting and protein microarrays (90-94). These include 175 
lipopolysaccharide (LPS) antigens, porins, lipoproteins, fimbriae, flagella, heat shock proteins and in some 176 
serovars, the Vi surface polysaccharide antigen (95, 96). Several antigens have been identified as targets 177 
of the protective antibody response. The O-antigen, consisting of sugar repeats exposed on the bacterial 178 
surface, is a prime target of protective antibodies with some epitopes being more protective than others. 179 
Immunodominant serovar-specific O-antigens (e.g. O:4, O:9) determine to a large extent the specificity of 180 
protection between serovars and induce antibodies that are more protective than the ones directed 181 
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against O-antigens shared among different Salmonella serogroups (e.g. O:12) (97-100). The Vi antigen is 182 
immunogenic and was shown to confer protective immunity in human volunteers and in field trials, both 183 
as a native polysaccharide and as a protein conjugate (49, 51, 53, 101-103).  184 
The functional role of the antibody response to porins is still not fully clarified. Antibody responses against 185 
some porins, but not others, are protective in animal models (104, 105). For example, antibodies to the 186 
trimeric OmpD porin, but not the monomeric and abundant OmpA protein, protect mice against 187 
parenteral challenge. Furthermore, OmpD is a candidate antigen for iNTS vaccines (20, 105, 106). The 188 
reasons for the different protective ability of OmpA and OmpD have been elegantly postulated to be due 189 
to different accessibility of antibodies to OmpD at the bacterial surface. Both OmpA and OmpD are located 190 
in the outer membrane of Salmonella in a position potentially shielded by the LPS-O side chain. However, 191 
OmpD creates a larger footprint than OmpA in the O-antigen layer, sufficient for a single IgG can gain 192 
access to the most-exposed surface loop epitopes of OmpD (105). It remains unclear how antibodies to 193 
OmpD mediate SBA given that at least two Ig need to come together for activation of the classical pathway 194 
of the complement. The conclusion that OmpA is poorly accessible by IgG also clashed with data showing 195 
its binding by human recombinant IgG specific for a mimotope inserted in OmpA (107).  196 
Antibodies to flagellin are detectable in infected individuals and targeting this antigen can mediate 197 
opsono-phagocytosis (87, 93).   198 
 199 
Which is the main protective mechanism of anti-Salmonella antibodies? 200 
Following their binding to the bacterial surface, antibodies can exert antibacterial efficacy mainly in two 201 
ways. Either by increasing phagocytosis of bacteria via targeting the bacteria to specific receptors on the 202 
surface of immune cells; or by direct bactericidal activity mediated by the activation of the classical 203 
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complement pathway (serum bactericidal activity, SBA).  Both these mechanisms are likely to operate in 204 
Salmonella infections. Early studies showed that clearance of Salmonella from the blood of mice is 205 
dramatically accelerated by immune serum suggesting a role for antibodies in the enhancement of 206 
phagocytosis (70). More recently, evidence for an enhancement of opsono-phagocytosis by Salmonella 207 
antibodies has been corroborated by in vitro systems. Sera from humans vaccinated with live attenuated 208 
S. Typhi enhance opsono-phagocytosis in vitro with IgG playing a major role(108). Engagement of 209 
opsonised bacteria with the activating Fc-gamma receptors, on the surface of murine or human 210 
phagocytes results in increased uptake of the bacteria, increased production of reactive oxygen 211 
intermediates (ROI) and enhanced antibacterial functions of the infected cells (87, 88, 107). Opsonization 212 
drives increases in both the number of phagocytes that ingest bacteria and in the efficiency of each 213 
individual cell to ingest Salmonella, as indicated by the higher intracellular numbers per phagocyte of 214 
opsonized versus non-opsonized bacteria (88, 107). Antibodies have also shown to be essential for optimal 215 
phagocytosis of iNTS strains by peripheral blood cells from Africans (55). 216 
Antibody-dependent, complement-mediated SBA correlates with susceptibility to iNTS in African children 217 
(56) and  therefore SBA has been often taken as an indication of the functional activity of antibodies when 218 
testing new vaccines against iNTS (109). However, the role of SBA as a true mechanism of antibody-219 
mediated protection must be evaluated with caution. Studies that used human blood and sera to compare 220 
the kinetics of SBA and phagocytosis of iNTS clinical isolates, show that phagocytosis allows bacteria to 221 
escape the blood and establish intracellular infection before they are killed by the complement membrane 222 
attack complex (110). This would indicate that opsono-phagocytosis is likely to be the prevailing 223 
antimicrobial mechanism mediated by anti-Salmonella antibodies. Furthermore, no correlation was found 224 
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between protection afforded by live vaccination and SBA in a controlled human typhoid challenge 225 
model(111). 226 
 227 
Complement or Fc-gamma receptors?  228 
The complement system and Fc-gamma receptors (FcγRs) can potentially play a crucial role in antibody-229 
mediated immunity against Salmonella diseases. However, their relative importance is unclear. 230 
Complement-mediated SBA can result in bacterial killing, but, as discussed above, it is unclear whether 231 
this mechanism is relevant for immunity to Salmonella. Complement appears to be essential for antibody 232 
dependent-opsonophagocytosis of iNTS strains by human blood phagocytes and for the production of 233 
reactive oxygen intermediates and bacterial killing (55). However, binding of antibody-opsonized 234 
Salmonella to FcgR on human and murine cells in the absence of complement also enhances phagocytosis 235 
and ROI-mediated bacterial killing, with the activating FcgRI playing a major role (88, 107).  236 
In vivo studies also provide evidence for a role for both complement and FcgR, their relevance depending 237 
on the experimental model used. When mice lacking FcγRI, II, III and IV (FcγR KO), or mice lacking the 238 
complement C3 component (C3 KO), or all four FcγR and C3 (FcγR/C3 KO), were passively immunized with 239 
anti-LPS O4 IgG2a monoclonal antibodies and subsequently infected parenterally with Salmonella 240 
Typhimurium, only FcγR KO animals showed a significant reduction in the bacterial loads in the liver, 241 
spleen and mesenteric lymph nodes (112), at a level similar to the ones observed in wild-type control 242 
animals. In this model therefore, the role of complement prevails on that of FcγRs. However, when mice 243 
lacking FcγRI, II, III and mice lacking C3 were immunised with a live attenuated vaccine and later 244 
challenged orally with virulent Salmonella, only the FcγR-deficient mice succumbed to the infection (113) 245 
indicating a prevailing role of FcγR. 246 
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In summary, evidence for a role of both FcγR and complement has been provided, but firm conclusions 247 
on their relative importance are difficult to draw due to discrepancies between experimental conditions, 248 
models and host species.   249 
 250 
Does quality of the antibody response matter?  251 
The qualitative traits of the antibody response have a great effect on its function and potency. The isotype 252 
profile has effects on the binding of antibodies to FcgR receptors and on efficiency of complement 253 
activation. This in turn has effects on SBA, opsono-phagocytosis and on the enhancement of the 254 
intracellular antibacterial mechanisms of phagocytes.  255 
Virtually all classes of Ig are produced in response to infection with Salmonella. As expected, IgM appear 256 
early after infection and usually followed by IgG and IgA (92, 95, 114-117).  Different isotype profiles are 257 
seen following natural infection or vaccination with live or non-living vaccines (22, 118). Some non-living 258 
vaccines can induce isotype-switched responses to Salmonella polysaccharide antigens indicating that the 259 
T-cell responses induced by these preparations may not be able to mediate the suppression of bacterial 260 
growth in the tissues, but are sufficient to support isotype switching of the Ig response. For example, IgG 261 
responses are detected following vaccination with Vi-conjugate vaccines (51, 119, 120); interestingly 262 
outer membrane vesicle vaccines (OMV) are capable of inducing highly effective IgG2a and IgG2b in mice 263 
(109); live vaccines induce high titers of all IgG subclasses including higher levels of IgG2a (22). 264 
The isotype profile of the antibody response impacts on its protective function. The efficacy of individual 265 
subclasses has been studied in murine and human systems and this area of research is not devoid of 266 
controversy. In murine studies, polyclonal and monoclonal IgM as well as IgA to Salmonella polysaccharide 267 
antigens, were found to be highly protective and in some cases more protective than IgG (100, 121, 122).  268 
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Conversely, opsonization of Salmonella with O4-specific IgA, IgG1, IgG2a, or IgG2b, but not IgM 269 
monoclonal antibodies, resulted in cell-dependent bacterial killing in vitro. In in vivo passive immunization 270 
studies, IgG2a and IgG2b O4-specific monoclonal antibodies provided higher functional activity than IgA, 271 
IgM and IgG1 by decreasing the bacterial load in the blood and tissues (123).  272 
A role for IgA in protection against Salmonella is shown by the increased susceptibility to infection of 273 
polymeric immunoglobulin receptor (pIgR−/−) knock-out mice, which are unable to bind and actively 274 
transport dimeric IgA to the mucosae (124) and by the protective ability of IgA monoclonal antibodies in 275 
vivo (125). 276 
The relative potency of individual isotypes can be dependent on the antigen that is targeted. In fact, 277 
differently for what seen in the case of antibodies against the LPS-O antigen, it has been shown that mice 278 
lacking IgG1, but not lacking IgG2a are substantially less protected after immunization with the OmpD 279 
porin than wild-type controls. Immunization with OmpD was maintained in t-bet deficient mice that do 280 
not produce IgG2a. This is consistent with IgG1 having an important role for protection after immunization 281 
with OmpD, but IgG2a being less important (126). 282 
The relative potency of human IgG was studied in an in vitro system where OmpA and flagella were tagged 283 
with a foreign CD52 mimotope (TSSPSAD). The bacteria were opsonized with a panel of humanized 284 
recombinant CD52 antibodies that share the same antigen-binding V-region, but have constant regions of 285 
different subclasses. This work revealed that, although opsonization with all the IgG subclasses increase 286 
Salmonella uptake by human phagocytes, differences in potency can easily be revealed. IgG3 resulted in 287 
the highest level of bacterial uptake and the highest average bacterial load per infected cell, which was 288 
closely followed by IgG1, then IgG4 and lastly IgG2. Phagocytosis mediated by IgG1, IgG3 and IgG4 had a 289 
higher dependency on FcgRI than FcgRIIA, whereas IgG2-mediated phagocytosis required FcgRIIA more 290 
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than FcgRI (87, 107). Therefore, both the subclass of human IgG and the type of FcgR that is available for 291 
antibody binding affects the function of anti-Salmonella antibodies.  292 
Some IgG subclasses can be detrimental to the antimicrobial function of the antibody response.  In fact, 293 
the inability of blood from HIV patients to kill Salmonella is due to an inherent inhibitory effect of anti-LPS 294 
antibodies. This inhibition is dependent on high concentrations of antibodies and strongly associated with 295 
IgA and IgG2 anti-LPS antibodies, possibly related to the poor ability of IgA and IgG2 to activate 296 
complement, and deposition of complement at sites where it cannot insert in the bacterial membrane 297 
(127). 298 
 299 
Crosstalk between B-cells and T-cells and quality traits of the antibody response.  300 
T-cell responses can be detected in animals and humans following infection with live Salmonella(128-301 
130).  Isotype switching and production of anti-protein antibodies requires the presence of T-cells (27, 302 
118); for example, T-cell deficient athymic mice produce mainly IgG3 and IgM antibodies to 303 
lipopolysaccharide, whereas euthymic mice can produce IgM, IgG1, IgG2a, IgG2b, and IgG3 anti-LPS and 304 
anti-Salmonella protein antibodies (27). Similarly, some classes of non-living vaccines only elicit a 305 
restricted isotype repertoire (22). The reciprocal interaction between T- and B-cells is essential for the 306 
development of both humoral and cell-mediated immunity to Salmonella (Figure 2). In the absence of 307 
functional B-cells, the onset of T-cell immunity is impaired, albeit not abrogated in mice (131-134). 308 
Cytokine production and antigen presentation via MHC Class II molecules from B-cells are essential for 309 
activation of Th1 and Th17 responses to Salmonella, as shown by studies in bone marrow chimera mice 310 
where only B-cells are deficient in selected immunological functions (135). Interestingly B-cells can 311 
engender T-cell responses via engagement of innate immune receptors early in infection and via specific 312 
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activation of the antigen-specific B-cell receptor later in the disease. These functions instigate a loop 313 
where T-cell activation in turn contributes to the isotype profile of the response. In fact, antigen-specific 314 
IgG2c primary response are dependent on MyD88 signaling to B cells, while other Ig classes are not (IgG1 315 
and IgG3) or much less so (IgG2b, IgA). Lack of MyD88 signaling in B-cells of chimeric mice results in 316 
impairment of development of IFNg effector T cells, a likely contributory factor in the lack of IgG2c (136).   317 
 318 
Key considerations for the development of Salmonella Vaccines. 319 
Antibodies are an essential component of the protective immune response to Salmonella. An ideal vaccine 320 
would therefore be the one able to induce both antibody responses and protective cellular immunity.  321 
The induction of some level of T-cell immunity is essential whichever the choice of vaccine. T-cell 322 
immunity induced by natural infection or live vaccines is sufficient to support the isotype switching and 323 
affinity maturation of the antibody response, but also to mediate the suppression of the growth of virulent 324 
bacteria when either resistant or susceptible animals are re-infected.  On the contrary, T-cell immunity 325 
induced by some non-living vaccines is sufficient to support isotype switching and anti-protein responses 326 
(109, 118), but not protective cellular responses. Why this level or type of T-cell immunity is unable to 327 
activate phagocytes and curtail bacterial net growth in the tissues, still remains one of the main 328 
unanswered questions in bacterial vaccinology.    329 
Antibodies alone can have an impact on the very early stages of the infection, when they enhance 330 
bacterial killing  before Salmonella have reached an intracellular location within phagocytes (46, 71); 331 
however they have no effect on the net growth of bacteria in the tissues and surprisingly on the control 332 
of bacteraemia (9, 46, 60, 71, 127, 137). Therefore, it is likely that in individuals who do not have specific 333 
Th1 memory, vaccine-induced antibody responses protect by preventing the establishment of the 334 
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infection following transmission of the pathogen. The situation would be different in populations where 335 
background cellular immunity is present. For example, those vaccines that induce mainly antibody 336 
responses would be more effective in disease-endemic areas, where a background of cellular immunity is 337 
already present in the population, likely due to low grade pre-exposure to the pathogen and/or cross-338 
reactive antigens of other micro-organisms. Interestingly, young African children develop Th1 immunity 339 
to Salmonella very early in life, but remain susceptible to iNTS until they acquire Salmonella-specific 340 
antibodies (57); the aim of an effective iNTS vaccine for children would therefore the be induction of 341 
antibodies early in life. A lower protective efficacy of Vi vaccines against typhoid fever has been detected 342 
in volunteers in a controlled human challenge study compared to field studies, further suggesting the 343 
possibility that a different immunological exposure background due to the geographical area may affect 344 
vaccine efficacy(102, 103, 138).     345 
The development of both safer live attenuated vaccines and non-living vaccines would be desirable; the 346 
former would be more suitable for travelers where elicitation de novo of both T- and B-cell immunity is 347 
required; the latter vaccines would be suitable for use in endemic areas where, as discussed earlier, 348 
increased safety is a prerequisite and induction of antibodies would suffice. 349 
Optimization of the immune response is important especially for non-living vaccines whose efficacy is 350 
likely to be entirely based on antibodies. The importance of the isotype profile in relation to antigen 351 
specificity and function has been touched upon above with some representative examples.  352 
Greater efforts are needed to optimize antibody responses induced by vaccines to be used in areas where 353 
immune suppressive co-morbidities co-localize geographically with the target disease. An example is 354 
provided by malaria. This disease has a dual effect on humoral immunity. Firstly, malaria can suppress the 355 
acquisition of anti-Salmonella antibodies (59, 139). Secondly, malaria can impair complement levels (61) 356 
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and suppress the antimicrobial functions of phagocytes (28, 58, 140), therefore potentially not allowing 357 
the expression of antibody-mediated resistance (55, 88). More research is needed to identify vaccine 358 
solutions that can overcome these problems. In fact, iNTS vaccines for Africa must induce immune 359 
responses optimized to confer resistance in the presence of multiple and varying underlying 360 
comorbidities. 361 
The optimal choice of antigens is still debatable and several single-antigen vaccines are being developed 362 
and/or are in use. For example, the vaccines based on the Vi polysaccharide are immunogenic and induce 363 
protective serum responses. However, these vaccines include a single antigen that is not essential for the 364 
virulence of the bacterium (Vi negative variants of  S. Typhi are capable of causing disease (141)) and is 365 
down-regulated within the tissues soon after infection (142). Multi-antigen vaccines would probably be a 366 
wiser choice than single-antigen ones and would also offer the possibility to induce antibody responses 367 
that can potentially protect against a large number of Salmonella serovars. For example, low-reactogenic 368 
outer membrane vesicle-based vaccines that contain multiple structural antigens are very immunogenic 369 
and elicit highly functional isotype-switched antibody responses against a variety of polysaccharide and 370 
protein determinants (109, 143).  371 
  372 
Conclusions.  373 
The overall scenario that emerges from decades of research in experimental animals and in humans 374 
indicates that antibodies are certainly essential for resistance against systemic Salmonella infections and 375 
can express the highest level of protective functions when operating in conjunction with T-cell mediated 376 
immunity. Antigen specificity, isotype profile, FcgR receptor usage and complement activation (Figure 3) 377 
are intertwined factors that have great influence on antibody-mediated protection to Salmonella.  378 
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There is still a large deal of discrepancy between findings and conclusions from different studies over 379 
several decades and this makes rational vaccine design very difficult. 380 
To improve current vaccines and design new ones in the future it will be necessary to shed light on the 381 
mechanisms that underpin both the development of antibody responses and their effector functions. It 382 
will also be necessary to learn how to tailor antibody responses to situations where other components of 383 
the immune system might be impaired, as often seen in endemic areas where immune-suppressive co-384 
morbidities geographically coincide with systemic Salmonella infections. Different vaccines and antibody 385 




Figure 1. The complex pathogenesis of Salmonella: an intracellular antibody-refractive growth phase 390 
and an extracellular antibody-susceptible phase of spread. A) After invading the gut, Salmonella reach 391 
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the blood where can be targeted by antibodies. Some bacteria in the blood are lysed by antibody- and 392 
complement-dependent serum bactericidal activity (SBA). B) Bacteria opsonised by antibodies are 393 
engulfed and killed more efficiently by resident phagocytes as soon as they reach the tissues (e.g. spleen, 394 
liver, bone marrow). C) Those bacteria that resist killing establish unicellular initial infection foci (infected 395 
phagocytes). Surviving bacteria grow mainly in an intracellular location. D) The initial single-cell infection 396 
foci become spatially separated multicellular pathological lesions due to the infiltration of 397 
polymorphonuclear phagocytes (PMNs) and later mononuclear cells. In this intracellular location bacteria 398 
are inaccessible to antibodies. Bacteria grow intracellularly within the multicellular infection foci, but their 399 
numbers within each phagocyte remain low due to the spread of the infection to infection of new host 400 
cells. E) Some bacteria escape the lesions, become vulnerable to antibodies and eventually spread at 401 
distant sites. When the bacteria are released from infected cells, they might undergo three different fates: 402 
I) be targeted by antibodies, and killed via complement-mediated SBA or opsonophagocytos; II) rapidly 403 
infect neighbouring cells within the same lesion; III) travel to distant sites in the body to establish new 404 




Figure 2. B-cells and T-cells crosstalk impact on quality of the antibody response. MyD88 signalling and 407 
recognition of bacterial antigens via B-cell Receptor (BcR) leads to B-cell cell activation and antigen 408 
presentation to naïve T-cells via MHC Class II molecules. IL6 and IFNg from B-cells mediate the 409 
development of Th immunity. Th immunity in turn triggers activation and maturation of B-cells and induce 410 




Figure 3. Antibody-mediated protection to Salmonella is underpinned by a complex interplay between 413 
qualitative traits and effector mechanisms. Antigen specificity, isotype profile, FcγR receptor usage, 414 
complement activation, and different effector mechanisms (opsonophagocytosis, killing via reactive 415 
oxygen intermediates (ROI) and serum bactericidal activity (SBA)) are intertwined factors that influence 416 
antibody-mediated protection to Salmonella. 417 
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